drugset / Trial / NCT03430466
Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the safety and efficacy of anti PD-L1 antibody + anti CTLA-4 antibody in combination with hormone therapy in patients with hormone receptor positive HER2-negative recurrent or metastatic breast cancer.
Timeline
- Start
- 2017-06-22
- Primary completion
- 2018-01-30
- Completion
- 2018-07-31
Outcome
Outcome not reported
Stopped (Enrollment): “Recruiting was not possible”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Tremelimumab | Monoclonal antibody | — | — |